Intelligence · Patents
Patents expiring in 2045
Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.
- Patents
- 1,566
Quick answer
1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 12391765
Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
granted -
US 12391760
Method of treating primary sclerosing cholangitis
granted -
US 12390453
Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
granted -
US 12389931
Oyster peptide with effect of improving sexual function and preparation method thereof
granted -
US 12390462
Muscarinic acetylcholine M1 receptor antagonists
granted -
US 12390463
Dosage forms and regimens for amino acid compounds
granted -
US 12390473
Methods of treating tyrosine kinase inhibitor-induced diarrhea
granted -
US 12391920
Models of tauopathy
granted -
US 12390419
Formulations of (R)-2-amino-3-phenylpropyl carbamate
granted -
US 12390509
Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof
granted -
US 12390524
Compositions and methods for inducing immune responses
granted -
US 12391753
Antigen binding molecule formats
granted -
US 12391923
SIRPα-silenced natural killer (NK) cells
granted -
US 12391654
CFTR regulators and methods of use thereof
granted -
US 12391720
Salts and polymorphs of cethromycin for the treatment of disease
granted -
US 12391742
Anti-KRAS-G12D T cell receptors
granted -
US 12389889
Mouse having a humanized cluster of differentiation 47 gene
granted -
US 12391642
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted -
US 12391732
Articles comprising a silk polypeptide for antigen delivery
granted -
US 12391741
T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
granted -
US 12391739
Method for producing gamma delta T cells
granted -
US 12391658
Sulfoxide and sulfone glucokinase activators and methods of use thereof
granted -
US 12391750
Anti-C1S antibodies and methods of use thereof
granted -
US 12391669
Substituted pyrimidines as IRE1 kinase inhibitors
granted -
US 12390512
Depolymerase capable of degrading extracellular polymeric substances of Klebsiella pneumoniae
granted -
US 12391686
Compounds and uses thereof
granted -
US 12390497
Microbial strains for virus inhibition
granted -
US 12390427
Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use
granted -
US 12391663
Isoindolinone compounds
granted -
US 12390483
Compounds and methods for treating neurological and cardiovascular conditions
granted -
US 12391643
Substituted amino-thiol and amino-disulfide compounds, and uses thereof
granted -
US 12391734
PD-1 homing endonuclease variants, compositions, and methods of use
granted -
AR 133027
COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UN COMPUESTO DE QUINAZOLINA
granted -
AR 133055
DOMINIOS VARIABLES ÚNICOS DE INMUNOGLOBULINA DIRIGIDOS A PD-L1
granted -
WO 2025172818
POLYTHÉRAPIE À BASE DE PYRILUTAMIDE
granted -
WO 2025172541
NOUVELLE COMPOSITION POUR L'AMÉLIORATION DE LA RECONSTITUTION DE LA MOELLE OSSEUSE ET DE LA RÉCUPÉRATION PÉRIPHÉRIQUE DES NUMÉRATIONS DE NEUTROPHILES ET DE PLAQUETTES
granted -
US 12397028
Adoptive cellular therapy
granted -
US 12396924
Adapter for use in a planetary mixer
granted -
US 12396949
Technology for improving properties of lipid nanoparticles using lipids in which cis-unsaturated bonds are substituted with a silicon atom
granted -
US 12396994
Compositions for improving physiological function with age
granted -
US 12398193
Targeted replacement of endogenous T cell receptors
granted -
US 12397066
Delivery of gene therapy treatments
granted -
US 12398123
Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria
granted -
US 12398194
Cell lexpressing two chimeric antigen receptors (CARs) at the cell surface
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12398179
Nanomolar peptides and derivatives to differentially modulate ephrin receptors
granted -
US 12398140
Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia
granted -
US 12398178
Collections of peptides, peptide agents, and methods of use thereof
granted
Frequently asked questions
How many pharma patents expire in 2045?
1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.